Literature DB >> 25549319

Insulin-like growth factor I reduces lipid oxidation and foam cell formation via downregulation of 12/15-lipoxygenase.

Sergiy Sukhanov1, Patricia Snarski2, Charlotte Vaughn2, Patricia Lobelle-Rich2, Catherine Kim2, Yusuke Higashi2, Shaw-Yung Shai2, Patrice Delafontaine2.   

Abstract

OBJECTIVE: We have shown that insulin-like growth factor I (IGF-1) infusion in Apoe(-/-) mice decreased atherosclerotic plaque size and plaque macrophage and lipid content suggesting that IGF-1 suppressed formation of macrophage-derived foam cells. Since 12/15-lipoxygenase (12/15-LOX) plays an important role in OxLDL and foam cell formation, we hypothesized that IGF-1 downregulates 12/15-LOX, thereby suppressing lipid oxidation and foam cell formation. APPROACH AND
RESULTS: We found that IGF-1 decreased 12/15-LOX plaque immunopositivity and serum OxLDL levels in Apoe(-/-) mice. IGF-1 reduced 12/15-LOX protein and mRNA levels in cultured THP-1 macrophages and IGF-1 also decreased expression of STAT6 transcription factor. IGF-1 reduction in macrophage 12/15-LOX was mediated in part via a PI3 kinase- and STAT6-dependent transcriptional mechanism. IGF-1 suppressed THP-1 macrophage ability to oxidize lipids and form foam cells. IGF-1 downregulated 12/15-LOX in human blood-derived primary macrophages and IGF-1 decreased LDL oxidation induced by these cells. IGF-1 reduced LDL oxidation and formation of foam cells by wild type murine peritoneal macrophages, however these effects were completely blocked in 12/15-LOX-null macrophages suggesting that the ability of IGF-1 to reduce LDL oxidation and foam cells formation is dependent on its ability to downregulate 12/15-LOX.
CONCLUSIONS: Overall our data demonstrate that IGF-1 reduces lipid oxidation and foam cell formation via downregulation of 12/15-LOX and this mechanism may play a major role in the anti-atherosclerotic effects of IGF-1. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Atherosclerosis; Foam cells; LDL/Oxidation/antioxidants; Lipoxygenase; Macrophages/monocytes; Oxidized lipids

Mesh:

Substances:

Year:  2014        PMID: 25549319      PMCID: PMC4298481          DOI: 10.1016/j.atherosclerosis.2014.12.024

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  38 in total

Review 1.  Role of IGF-I in skeletal muscle mass maintenance.

Authors:  David R Clemmons
Journal:  Trends Endocrinol Metab       Date:  2009-09-02       Impact factor: 12.015

Review 2.  Roles of unphosphorylated STATs in signaling.

Authors:  Jinbo Yang; George R Stark
Journal:  Cell Res       Date:  2008-04       Impact factor: 25.617

Review 3.  Isoprostanes and other markers of peroxidation in atherosclerosis.

Authors:  Paola Patrignani; Stefania Tacconelli
Journal:  Biomarkers       Date:  2005-11       Impact factor: 2.658

4.  Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.

Authors:  Steven D Chernausek; Philippe F Backeljauw; James Frane; Joyce Kuntze; Louis E Underwood
Journal:  J Clin Endocrinol Metab       Date:  2006-12-27       Impact factor: 5.958

5.  Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice.

Authors:  T Cyrus; D Praticò; L Zhao; J L Witztum; D J Rader; J Rokach; G A FitzGerald; C D Funk
Journal:  Circulation       Date:  2001-05-08       Impact factor: 29.690

6.  12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice.

Authors:  J George; A Afek; A Shaish; H Levkovitz; N Bloom; T Cyrus; L Zhao; C D Funk; E Sigal; D Harats
Journal:  Circulation       Date:  2001-10-02       Impact factor: 29.690

7.  Decreased expression of insulin-like growth factor-1 and apoptosis of vascular smooth muscle cells in human atherosclerotic plaque.

Authors:  Y Okura; M Brink; A A Zahid; A Anwar; P Delafontaine
Journal:  J Mol Cell Cardiol       Date:  2001-10       Impact factor: 5.000

8.  IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice.

Authors:  Sergiy Sukhanov; Yusuke Higashi; Shaw-Yung Shai; Charlotte Vaughn; Jessica Mohler; Yangxin Li; Yao-Hua Song; Jane Titterington; Patrick Delafontaine
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-10-04       Impact factor: 8.311

9.  Novel lipoxygenase inhibitors as neuroprotective reagents.

Authors:  Klaus van Leyen; Ken Arai; Guang Jin; Victor Kenyon; Bettina Gerstner; Paul A Rosenberg; Theodore R Holman; Eng H Lo
Journal:  J Neurosci Res       Date:  2008-03       Impact factor: 4.164

10.  Growth hormone-releasing peptide-2 suppresses vascular oxidative stress in ApoE-/- mice but does not reduce atherosclerosis.

Authors:  Jane S Titterington; Sergiy Sukhanov; Yusuke Higashi; Charlotte Vaughn; Cyril Bowers; Patrice Delafontaine
Journal:  Endocrinology       Date:  2009-10-09       Impact factor: 4.736

View more
  10 in total

Review 1.  IGF-1 and cardiovascular disease.

Authors:  Yusuke Higashi; Sandeep Gautam; Patrick Delafontaine; Sergiy Sukhanov
Journal:  Growth Horm IGF Res       Date:  2019-01-31       Impact factor: 2.372

2.  Serum paraoxonase level and paraoxonase polymorphism in patients with acromegaly.

Authors:  Dilek Arpaci; Sevim Karakas Celik; Murat Can; Esra Ermiş; Fatih Kuzu; Furuzan Kokturk; Ayse Ceylan Hamamcioglu; Ahmet Dursun; Taner Bayraktaroglu
Journal:  Redox Rep       Date:  2016-02-15       Impact factor: 4.412

3.  Ox-LDL Upregulates IL-6 Expression by Enhancing NF-κB in an IGF2-Dependent Manner in THP-1 Macrophages.

Authors:  Yan-Chao Wang; Yan-Wei Hu; Yan-Hua Sha; Ji-Juan Gao; Xin Ma; Shu-Fen Li; Jia-Yi Zhao; Yu-Rong Qiu; Jing-Bo Lu; Chuan Huang; Jing-Jing Zhao; Lei Zheng; Qian Wang
Journal:  Inflammation       Date:  2015-12       Impact factor: 4.092

4.  Macrophage-Specific IGF-1 Overexpression Reduces CXCL12 Chemokine Levels and Suppresses Atherosclerotic Burden in Apoe-Deficient Mice.

Authors:  Patricia Snarski; Sergiy Sukhanov; Tadashi Yoshida; Yusuke Higashi; Svitlana Danchuk; Bysani Chandrasekar; Di Tian; Vikara Rivera-Lopez; Patrick Delafontaine
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-12-02       Impact factor: 8.311

5.  Protein Biomarkers and Risk of Atrial Fibrillation: The FHS.

Authors:  Laila Staerk; Sarah R Preis; Honghuang Lin; Steven A Lubitz; Patrick T Ellinor; Daniel Levy; Emelia J Benjamin; Ludovic Trinquart
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-01-15

6.  Whole Body Vibration Retards Progression of Atherosclerosis via Insulin-Like Growth Factor 1 in Apolipoprotein E-Deficient Mice.

Authors:  He Wu; Yibo Zhang; Xuan Yang; Xian Li; Zhenya Shao; Zipeng Zhou; Yuanlong Li; Shuwen Pan; Chang Liu
Journal:  Biomed Res Int       Date:  2018-03-07       Impact factor: 3.411

7.  15-oxoeicosatetraenoic acid mediates monocyte adhesion to endothelial cell.

Authors:  Guohua Ma; Bing Pan; Sufen Ren; Caixia Guo; Yansong Guo; Lixin Wei; Lemin Zheng; Buxing Chen
Journal:  Lipids Health Dis       Date:  2017-07-12       Impact factor: 3.876

8.  Myokines in Acromegaly: An Altered Irisin Profile.

Authors:  Łukasz Mizera; Jowita Halupczok-Żyła; Katarzyna Kolačkov; Agnieszka Zembska; Jędrzej Grzegrzółka; Diana Jędrzejuk; Marek Bolanowski; Jacek Daroszewski
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-02       Impact factor: 5.555

9.  Construction and Analysis of lncRNA-Associated ceRNA Network in Atherosclerotic Plaque Formation.

Authors:  Danyu Li; Yunci Ma; Weiqian Deng; Jianhua Feng
Journal:  Biomed Res Int       Date:  2022-04-15       Impact factor: 3.246

10.  Bifunctional supramolecular nanofiber inhibits atherosclerosis by enhancing plaque stability and anti-inflammation in apoE-/- mice.

Authors:  Yuna Shang; Chuanrui Ma; Jing Zhang; Zhongyan Wang; Chunhua Ren; Xin Luo; Rong Peng; Jingfei Liu; Jingyuan Mao; Yang Shi; Guanwei Fan
Journal:  Theranostics       Date:  2020-08-13       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.